Research peptide
BPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulatory posture require careful separation from social-media claims.
Track public claims, regulatory status, and source quality. Do not publish dosing, sourcing, or treatment instructions.
Frequently discussed in online recovery and longevity content.
Scheduled for FDA advisory committee discussion in July 2026.
Should be treated as a high-review topic until the regulatory picture is clearer.
Evidence level: Public discussion / regulatory watch
Sources: U.S. Food and Drug Administration, U.S. Food and Drug Administration
The page should explain the claim ecosystem without presenting it as medical advice.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Refresh after the advisory committee meeting record is available.
Source records are stored in the repo and linked from each claim.
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.